Alzheimers Disease Market Research- Identifying and Commercializing First-in-Class Innovation: Radiant Insights Inc.

Radiant Insights has announced the addition of “Frontier Pharma: Alzheimer’s Disease – Identifying and Commercializing First-in-Class Innovation” Market Research report to their database

The active Alzheimer’s Disease (AD) pipeline is populated with 583 products, with a highly diverse range of molecular targets. GBI Research analysis revealed a high degree of innovation in this indication, with 46% of the pipeline being first-in-class products, acting on over 40 first-in-class molecular targets. In addition, the pipeline is characterized by the strong presence of therapies that target multiple components implicated in the amyloid cascade, several molecular targets of which are known to trigger familial AD.

Read Complete Report with TOC at:
http://www.radiantinsights.com/research/frontier-pharma-alzheimer-s-disease-identifying-and-commercializing-first-in-class-innovation

Given that the currently approved therapies for AD are limited to acetylcholinesterase inhibitors and glutamate receptor antagonists, the pipeline offers a broad range of treatment options that may possess disease-modifying properties. However, evaluation of the Preclinical and clinical evidence for their therapeutic potential reveals that the novelty of the molecular target is not sufficient to effectively reduce the rate of AD progression in human patients.

Programs undergoing Preclinical development exhibit diverse disease-modifying mechanisms of action, and many represent strong alternatives to targets with a direct role in the amyloid and tau processes due to their roles in promoting neuronal survival and plasticity, a process critical to memory and cognition. Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) are considered promising targets in AD, primarily due to their potency in exhibiting significant neuroprotective effects in Preclinical studies.

Read More Sample Reports with TOC at:
http://www.radiantinsights.com/catalog/healthcare

Members of the caspase-mediated apoptotic cascade also show therapeutic potential, as early investigations have revealed an ability to modulate molecular mechanisms underlying synaptic plasticity in animal models, which translates into amelioration of behavioral deficits. Thus, growing insights into disease-causing processes in AD are being translated into a growing population of innovative therapeutic targets, as reflected in the highly innovative pipeline.

Latest Report by Radiant Insights

Asthma Therapeutics in Major Developed Markets to 2020 – Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations:
http://www.radiantinsights.com/research/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations

The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.

Market Digest: Aesthetic Lasers and Energy Devices Market 2006 to 2020 – Americas:
http://www.radiantinsights.com/research/market-digest-aesthetic-lasers-and-energy-devices-market-2006-to-2020-americas

The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: US, Brazil, Mexico and Canada. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

See this report on LinkedIn at:
https://www.linkedin.com/pulse/alzheimers-disease-market-research-radiant-insights-inc-jyoti-gaikwad

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: sales@radiantinsights.com
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: Califonia
Country: United States
Website: http://www.radiantinsights.com/research/frontier-pharma-alzheimer-s-disease-identifying-and-commercializing-first-in-class-innovation

Source: ABNewswire

ReleaseID: 30616